Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Neurology India
Mean body weight reduction reached approximately 24 percent at the highest dose tier a magnitude that, investigators have noted, exceeds the Phase 2 outcomes reported for dual GLP-1/GIP agonists at comparable trial durations (PMID 37366315)
See full terms and conditions at galaglp1.com
Were making effective weight loss accessible to our Bluffton community
Side Effects & Safety Transient headache -- the most commonly reported side effect Mild nausea -- usually resolves within 30 minutes Temporary dizziness/vertigo -- reported at higher doses Injection site redness -- standard for SC peptides No lethal dose identified in animal studies No dependency or withdrawal documented No respiratory depression -- unlike pharmaceutical sleep aids DSIP appears on the FDA's list of bulk drug substances that raise potential safety concerns
US$ 22.79
US$ 24.17
US$ 24.48
US$ 21.99
US$ 29.09
US$ 21.92
US$ 20.81
US$ 21.64
US$ 28.34
